International Non-Proprietary Name (INN): Heptor
Dosage Form: tablets (500 mg)
1 pill contains:
Active ingredients: ademethionine (in the form of S-adenosyl methionine) 400 mg.
Excipients: crospovidone (polyplasdone XL-10), microcrystalline cellulose, mannitol, magnesium stearate.
Shell composition: acryl-eze, hydroxypropyl methylcellulose, copovidone (plasdone S-630), polyethylene glycol 6000.
Yellow coated tablets, oblong. Two layers are visible in the cross section.
Pharmacological classification: antidepressant, hepatoprotector
ATC code: A16AA02
Pharmacological action: antidepressant, hepatoprotective
Heptor belongs to the group of hepatoprotectors. It has the antidepressant action, as well as detoxifying, regenerating, antioxidant, antifibrotic and neuroprotective effects.
Ademethionine is involved in biochemical processes of the body, while stimulating the production of endogenous ademethionine. Ademethionine (S-adenosyl-L-methionine) is a biological substance found in all tissues and fluids of the body. Its molecule is included in most biological reactions both as a methyl group donor - phospholipid methylation in the lipid layer of the cell membrane (transmethylation), and as a precursor to physiological thiol-containing compounds - cysteine, taurine, glutathione, one of the most important intracellular antitoxic agents, CoA, etc. (trans-sulfation), and as a precursor of polyamines - putrescine, which stimulates cell regeneration and proliferation of hepatocytes, spermidine, spermine, which are part of the structure of ribosomes (amino propylation).
- Intrahepatic cholestasis;
- Hepatitis of various origins: toxic (including alcoholic), viral, drug-induced (antibiotics, antitumor, antituberculosis and antiviral drugs, tricyclic antidepressants, oral contraceptives);
- Precirrotic conditions;
- Hepatic cirrhosis;
- Encephalopathy of secondary origin;
- Depressive syndromes, including secondary ones;
- Alcohol withdrawal syndrome.
Hypersensitivity to the drug ingredients.
Dosage and administration
Inside, swallow in the whole, without chewing. To improve the therapeutic effect, tablets are recommended to be taken between meals. During the period of the maintenance therapy, the recommended daily dose is 800–1600 mg (2–4 tablets). The duration of the maintenance therapy is an average of 2-4 weeks.
Side effects (rare)
Due to the fact that the active ingredient of the drug has an acidic pH, some patients may experience discomfort in the epigastric region when taking Heptor. In any case, these feelings are short-term; they are not pronounced and should not serve as a reason to stop the course of treatment.
Liver function abnormalities
Systematic monitoring of blood nitrogen level is necessary when prescribing Heptor to patients with the liver cirrhosis in the setting of hyperazotemia.
Pregnancy and lactation
Heptor is not recommended in the I-II trimester of pregnancy and during breastfeeding.
Given the tonic effect of Heptor, the drug is not recommended for use before bedtime. Heptor tablet should be removed from the package immediately before use.
K74 Fibrosis and cirrhosis of liver, K72.9 Hepatic failure, unspecified, B19 Unspecified viral hepatitis, F10.3 Withdrawal state, F10.2 Alcohol dependence syndrome, F32 Depressive episode, K73.9 Chronic hepatitis, unspecified, K76.9 Liver disease, unspecified, T36 Poisoning by systemic antibiotics, T37.5 Antiviral drugs, T38.4 Oral contraceptives, T43.0 Tricyclic and tetracyclic antidepressants, T45.1 Antineoplastic and immunosuppressive drugs, T37.1 Antimycobacterial drugs, G93.4 Encephalopathy, unspecified, K70 Alcoholic liver disease, K71.0 Toxic liver disease with cholestasis, K71 Toxic liver disease.
Keep in a dry, dark place at a temperature not exceeding 25 °C. Keep out of the reach of children.